En un párrafo
Tune does not change the letters of DNA at all. It changes the chemical marks that tell a cell how loudly to read a gene. Its lead programme aims to silence hepatitis B virus inside liver cells, which would be a durable treatment without any permanent change to the patient's own genome.
Tune Therapeutics develops epigenetic editing using dCas fusions to chromatin-modifying domains. Its lead programme, Tune-401, targets chronic hepatitis B by silencing viral DNA in hepatocytes, and has entered early clinical trials — among the first epigenetic editing programmes to reach patients.
Sources
- Tune Therapeutics
Tune Therapeutics ↗
No es asesoramiento de inversión
Este perfil es información educativa recopilada a partir de comunicaciones públicas. No es una recomendación de comprar, vender o mantener ningún valor, ni una opinión sobre las perspectivas de la empresa. La biotecnología es altamente especulativa y la mayoría de los programas clínicos fracasan.
Avisos legales completos →